logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Infantile Spasms

    FiltersReset Filters
    5 results

    • sabril

      (vigabatrin)
      Lundbeck Pharmaceuticals LLC
      Usage: SABRIL is indicated as adjunctive therapy for adults and children (2 years and older) with refractory complex partial seizures and as monotherapy for infants (1 month to 2 years) with infantile spasms, where benefits outweigh the risk of vision loss. Not a first-line treatment for complex partial seizures.

    • vigabatrin

      (vigabatrin)
      Zydus Lifesciences Limited
      Usage: Vigabatrin for oral solution is indicated as adjunctive therapy for refractory complex partial seizures in adults and children (2 years and older) not responding to other treatments, and as monotherapy for infantile spasms in children (1 month to 2 years). Vision loss risks must be considered.

    • vigabatrin

      (vigabatrin)
      Cipla USA, Inc.
      Usage: Vigabatrin for oral solution is indicated as adjunctive therapy for refractory complex partial seizures in patients 2 years and older, and as monotherapy for infantile spasms in children 1 month to 2 years old, where benefits outweigh the risks of vision loss.

    • vigabatrin

      (vigabatrin)
      Zydus Pharmaceuticals (USA) Inc.
      Usage: Vigabatrin is indicated as adjunctive therapy for adults and children (2 years and older) with refractory complex partial seizures, and as monotherapy for pediatric patients (1 month to 2 years) with infantile spasms. Vision loss risks must be considered against potential benefits. Not a first-line treatment for CPS.

    • vigabatrin

      (vigabatrin)
      Novadoz Pharmaceuticals LLC
      Usage: Vigabatrin for oral solution is indicated as adjunctive therapy for adults and pediatric patients (2 years and older) with refractory complex partial seizures and as monotherapy for infants (1 month to 2 years) with infantile spasms, when potential benefits outweigh the risk of vision loss.